Metabolic Syndrome

Grundy, Scott M.

doi:10.1007/978-3-030-36694-0_3

Cited by 10 publications

(11 citation statements)

References 237 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although 33% of the study population were receiving statins, this is unlikely to have impacted HDL-C and triglyceride levels as statins predominantly act on LDL-C. 28 Importantly, a key clinical consideration is that lifestyle interventions resulting in weight loss are the most effective interventions that will simultaneously reduce all these abnormalities. 29,30 In contrast, although medications also help minimise cardio-metabolic risk, they individually act on fewer risk factors (MetS components) and obviously have potential side-effects and compliance issues. The proportions of individuals with MetS were roughly 17% higher among Māori/Pacific peoples than in other ethnic subgroups, reflecting the different rates of T2DM and CVD found in NZ populations.…”

Section: Discussionmentioning

confidence: 99%

They’re sicker than we think: an exploratory study profiling the cardio-metabolic health in a sample of adults with pre-diabetes in Aotearoa New Zealand

Barthow

Pullon

Weatherall

et al. 2022

J. Prim. Health Care

View full text Add to dashboard Cite

Introduction. Type 2 diabetes mellitus (T2DM) is a highly prevalent and potentially preventable condition associated with significant health, social, and economic costs. The detection and management of pre-diabetes is an important opportunity to prevent or delay the onset of T2DM and associated morbidities; however, its importance is controversial as the health risks associated with pre-diabetes are poorly understood. Aim. To understand the cardio-metabolic health profile of a sample of adults with pre-diabetes in Aotearoa New Zealand. Methods. Secondary analyses of baseline data from all 153 adults recruited to an intervention trial for adults with pre-diabetes were carried out. A profile of cardio-metabolic risk was measured by describing the proportion with metabolic syndrome (MetS) calculated using Adult Treatment Panel III criteria, which includes blood pressure, lipids, and obesity in addition to glycaemic measures. The severity of MetS was calculated as MetS Z-scores. Subgroup analyses for sex, ethnicity and glycated haemoglobin (HbA 1c ) were performed. Results. Overall, 74% of this study population had MetS, and the proportion varied according to ethnicity and HbA 1c level. The severity of MetS was highly variable, with MetS-Z-scores ranging from −1.0 to 2.8. Although mean MetS Z-scores differed according to ethnicity and HbA 1c level, all subgroups included individuals with widely differing severity of MetS, suggesting likely quite different risks for progression to diabetes or cardiovascular disease across the range of pre-diabetes defined by HbA 1c . Discussion. Single biochemical markers of glycaemia are insufficient to ascertain overall cardio-metabolic risk when prioritising clinical efforts for those with pre-diabetes, particularly in primary care, where the potential for preventing or delaying the onset of type 2 diabetes mellitus (T2DM) is significant. Findings indicate the importance of attending to all cardiometabolic risk factors when caring for people with pre-diabetes. The development of tools using multiple relevant variables and predicting a comprehensive range of outcomes would improve timely risk stratification and treatment effect monitoring of pre-diabetes populations.

show abstract

Section: Discussionmentioning

confidence: 99%

They’re sicker than we think: an exploratory study profiling the cardio-metabolic health in a sample of adults with pre-diabetes in Aotearoa New Zealand

Barthow

Pullon

Weatherall

et al. 2022

J. Prim. Health Care

View full text Add to dashboard Cite

show abstract

“…On the other hand, gut metabolic syndromes are multiple risk factors like dyslipidemia, hyperglycemia, oxidative stress, insulin resistance, hypertension, fatty liver, etc. These syndromes result in metabolic diseases such as diabetes, obesity, hepatopathy, nephropathy, inflammation, cardiomyopathy, neurodegeneration, and osteoarthritis [ 29 , 30 , 31 ]. Metabolic syndromes are one of the concerning issues in the world as their prevalence is increasing day by day.…”

Section: Metabolic Syndromementioning

confidence: 99%

Curcumin, Quercetin, Catechins and Metabolic Diseases: The Role of Gut Microbiota

et al. 2021

View full text Add to dashboard Cite

Polyphenols (PPs) are the naturally occurring bioactive components in fruits and vegetables, and they are the most abundant antioxidant in the human diet. Studies are suggesting that ingestion of PPs might be helpful to ameliorate metabolic syndromes that may contribute in the prevention of several chronic disorders like diabetes, obesity, hypertension, and colon cancer. PPs have structural diversity which impacts their bioavailability as they accumulate in the large intestine and are extensively metabolized through gut microbiota (GM). Intestinal microbiota transforms PPs into their metabolites to make them bioactive. Interestingly, not only GM act on PPs to metabolize them but PPs also modulate the composition of GM. Thus, change in GM from pathogenic to beneficial ones may be helpful to ameliorate gut health and associated diseases. However, to overcome the low bioavailability of PPs, various approaches have been developed to improve their solubility and transportation through the gut. In this review, we present evidence supporting the structural changes that occur after metabolic reactions in PPs (curcumin, quercetin, and catechins) and their effect on GM composition that leads to improving overall gut health and helping to ameliorate metabolic disorders.

show abstract

“…Excessive energy intake and lack of exercise result in a positive energy balance which leads to the accumulation of visceral fat, the progression of liver steatosis and the onset of MetS risk factors [ 4 ]. Since the prevalence of these metabolic dysfunctions is continuing to increase, the discovery of new strategies for the prevention or treatment of MetS risk factors is of importance [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Brown Seaweeds Ascophyllum nodosum and Fucus vesiculosus in the Prevention or Delay Progression of the Metabolic Syndrome: A Review of Clinical Trials

et al. 2021

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a global public health problem affecting nearly 25.9% of the world population characterised by a cluster of disorders dominated by abdominal obesity, high blood pressure, high fasting plasma glucose, hypertriacylglycerolaemia and low HDL-cholesterol. In recent years, marine organisms, especially seaweeds, have been highlighted as potential natural sources of bioactive compounds and useful metabolites, with many biological and physiological activities to be used in functional foods or in human nutraceuticals for the management of MetS and related disorders. Of the three groups of seaweeds, brown seaweeds are known to contain more bioactive components than either red and green seaweeds. Among the different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans. This review intends to provide an overview of the potential of brown seaweed extracts Ascophyllum nodosum and Fucus vesiculosus for the management and prevention of MetS and related conditions, based on the available evidence obtained from clinical trials.

show abstract

Metabolic Syndrome

Cited by 10 publications

References 237 publications

They’re sicker than we think: an exploratory study profiling the cardio-metabolic health in a sample of adults with pre-diabetes in Aotearoa New Zealand

They’re sicker than we think: an exploratory study profiling the cardio-metabolic health in a sample of adults with pre-diabetes in Aotearoa New Zealand

Curcumin, Quercetin, Catechins and Metabolic Diseases: The Role of Gut Microbiota

Clinical Efficacy of Brown Seaweeds Ascophyllum nodosum and Fucus vesiculosus in the Prevention or Delay Progression of the Metabolic Syndrome: A Review of Clinical Trials

Contact Info

Product

Resources

About